Indegene Limited — Investor Meet, 28-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Indegene reports strong FY26 financials with INR 3,510.5 Cr revenue, demonstrating a 29.4% revenue CAGR (FY21-26) and 19.4% adjusted EBITDA margin. Net Revenue Retention consistently exceeded 100%. The company is strategically positioned for the AI Decade, leveraging its domain expertise as the pharma industry shifts towards centralized Sales & Marketing. Indegene aims to capture a larger market share by displacing agencies and CROs with its AI-embedded, outcome-aligned solutions. Management anticipates a 17% stronger pipeline for FY27, focusing on client migration and M&A for continued growth, projecting a confident outlook.